---

Market Overview

---

The global insulin pump market was valued at USD 3.68 billion in 2022 and is projected to reach USD 6.00 billion by 2028, growing at a CAGR of 8.46% during the forecast period. The steady increase in the prevalence of Type 1 diabetes is a key factor driving the adoption of insulin pumps and fueling market growth. Millions of Type 1 diabetes patients worldwide are already using insulin pumps. Furthermore, ongoing research and development in diabetes technologies have led to significant advancements in insulin pumps, contributing to the market’s growth.

The diabetes care sector is experiencing notable changes, with one of the revolutionary technologies being the continuous subcutaneous insulin delivery system provided by insulin pumps. These pumps are transforming the landscape of diabetes care and management. Moreover, continuous technological advancements offer promising opportunities for high adoption rates in the coming years. Currently, insulin pumps are primarily meeting the needs of the Type 1 diabetic population, while the adoption rate among Type 2 diabetic patients remains minimal. Available products in the industry have not adequately addressed the needs of Type 2 diabetic patients, resulting in a steady or declining adoption rate. However, insulin pump manufacturers are introducing products specifically designed for Type 2 diabetic patients, which is expected to drive demand in the future. The introduction of insulin pumps with glucose sensors and continuous monitoring provides valuable insights for predicting glucose levels.

However, the high cost of insulin pumps serves as a limiting factor for market growth. Additionally, the availability of alternative methods significantly hampers the widespread use of insulin pumps.

The insulin pump market is constantly evolving with new features and technological advancements. Major industry players such as Medtronic, Tandem Diabetes Care, and Insulet Corporation have been continuously advancing their technologies and introducing new products in recent years.

Research and development in the field, as well as published studies on closed-loop systems with insulin pumps for diabetes management, present new opportunities for market growth. Several hybrid systems associated with insulin delivery are expected to be commercialized in the future. Various systems, including DBLG1 (Diabeloop, Grenoble, France) for the adult Type 1 diabetes patient population and products like insulin-only iLet (Beta Bionics, the US) and Omnipod Horizon (Insulet, Billerica, the US), are currently undergoing clinical trials and are anticipated to enter the market in the future.

Type 1 diabetes patients heavily rely on external insulin delivery support, making them a significant driver of insulin pump market growth. The global prevalence of diabetes among adults aged 20 to 79 years increased from approximately 151 million (4.6% of the global population) in 2000 to around 537 million (10.5%) in 2021. It is projected that by 2030, the global diabetes population will reach around 643 million and could rise to approximately 783 million (12.2%) by 2045 if the prevalence rate remains the same.

Government initiatives aimed at improving diabetes care management play a crucial role in driving the growth of the insulin pump market. In response to the growing burden of diabetes worldwide, governments and public and private entities have increased their efforts to enhance diabetes healthcare. These initiatives include funding support for comprehensive, equitable, affordable, quality care and medical and technology-based treatments.

The cost of insulin pumps and associated insulin solutions is relatively higher compared to other insulin delivery solutions due to their advanced features. However, favorable reimbursement policies and healthcare insurance coverage strongly support the adoption of insulin pumps. In many countries, these policies alleviate the financial burden on patients and accelerate the adoption of insulin pumps. Insurance coverage typically includes both the cost of the insulin pump itself and the consumables required. This positive trend contributes to the rapid growth of the insulin pump market.

---

Market Segmentation

---

The market is segmented based on various factors, including products, disease, end-users, and geography.

Segmentation By Products
Pump – Tethered Pump, Patch Pump
Consumables

Segmentation By Disease
Type 1 Diabetes
Type 2 Diabetes

Segmentation By End-Users
Hospital
Home Healthcare Settings
Others

Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey

The global insulin pump market is divided into two main segments: pumps and consumables. Insulin pumps, which are widely used in diabetes management, account for a significant 65.85% of industry share. The adoption of insulin pumps for type 1 diabetes patients is steadily increasing, driving the growth of this segment. With the growing prevalence of diabetes and the burden it places on healthcare systems, there is a rising demand for new technologies in diabetes care delivery.

The advancements in insulin pumps present a valuable opportunity for both diabetes patients and healthcare professionals. These pumps not only lead to better clinical outcomes in diabetes management but also increase patients’ and medical professionals’ confidence in self-medication for diabetes care. They reduce hospital visits and associated costs, offering freedom from injections and interventions that require time to heal and administer care. Insulin pumps with advanced features are now available worldwide, providing several advantages. Technological advancements, shifting preferences of diabetes patients towards insulin pumps for insulin delivery, and favorable reimbursement policies are among the factors driving the growth of this segment.

The global insulin pump market is segmented by patients into Type 1 diabetes and Type 2 diabetes. Type 1 diabetes dominates this segment, with a value of USD 3.33 billion in 2022. Insulin pumps play a crucial role in managing type 1 diabetes, offering better glycemic control compared to multiple daily injections. Children are a major target population for continuous subcutaneous insulin infusion through insulin pumps. Additionally, insulin pumps have shown improved glycemic control in pediatric type 1 diabetes patients, leading to significant demand. Type 1 diabetes patients heavily rely on external insulin delivery support due to their inability to produce insulin. In developed countries, a majority of insulin-dependent type 1 diabetes patients have embraced the use of insulin pumps over alternative methods, contributing to the market’s growth.

Hospitals are the dominant end-users in the insulin pump market, accounting for 51.82% of the market share. They play a significant role in insulin pump adoption as a large number of patients rely on hospital settings for diabetes management. As the prevalence of diabetes continues to rise, the demand and popularity of diabetes management devices, particularly insulin pumps, are increasing within the medical community. Insulin pumps have demonstrated significant medical outcomes through appropriate insulin delivery in both type 1 and type 2 diabetes patients, leading to an improved quality of life compared to traditional and alternative methods. These factors contribute to the high consumption of insulin pumps in hospital settings and drive segmental growth.

North America is the leading region in the global insulin pump market, with a high usage of insulin pumps among various demographics affected by diabetes. The region’s substantial burden of diabetes management and higher healthcare expenditure accelerate the adoption of insulin pumps. In the United States alone, one in three type 1 diabetes patients uses insulin pumps, accounting for over 30% of the country’s type 1 diabetes patient population using these devices. Factors such as research and development advancements in insulin pumps, increased expenditure on diabetes care and management, and government initiatives fuel industry growth in North America.

In Europe, the insulin pump market was valued at USD 1.17 billion in 2022. Domestic and international market players in Europe have initiated innovative clinical research in insulin pump therapy, particularly when the adoption of insulin pumps was limited in previous decades. The increasing prevalence of type 1 diabetes in European countries is driving the acceptance of insulin pumps. Moreover, countries like Germany, France, the UK, Italy, Spain, and the Netherlands have witnessed increased expenditure on diabetes management, creating lucrative market growth opportunities.

The Asia-Pacific (APAC) region is experiencing rapid growth in the insulin pump market due to its significant volume of diabetes patients and rising healthcare expenditure on diabetes. In Southeast Asia, approximately 90 million adults have diabetes, while in the Western Pacific region, there are around 206 million diabetes patients as of 2021. In 2022, APAC accounted for a 20.90% market share in the global insulin pump market. China is a dominant player in the insulin pump market due to its high healthcare expenditure and largest diabetes patient population globally. Additionally, greater access and continuous development of insulin pump delivery devices in APAC have increased awareness among the population.

---

Competitive Landscape

---

The global insulin pump market demonstrates a high level of consolidation, characterized by a limited number of key players. The market is witnessing the introduction of various innovative products, including patch pumps, which are being well-received and adopted at a comparatively higher rate. Tandem Diabetes Care stands out as one of the prominent companies operating in the insulin pump market. It is estimated that approximately 750,000 individuals in the United States currently utilize an insulin pump, with Tandem Diabetes Care being a significant contributor to this figure. Furthermore, the company has reported that more than 450,000 people across 20 countries outside the United States also rely on their insulin pumps. Tandem Diabetes Care’s insulin pump enjoys wide availability in the global market.

Another major player in the insulin pump market is Insulet, which holds a substantial market share. The company offers technologically advanced and state-of-the-art insulin delivery systems, positioning itself as one of the leading players in the market. In the United States, where only three companies commercialize insulin pumps for managing both Type 1 and Type 2 diabetes patients, Medtronic is recognized as one of the dominant companies. Medtronic offers durable insulin pumps such as the MiniMed 770G, along with older models like the MiniMed 630G and 670G.

Key companies profiled in this report include Insulet Corporation, Medtronic, Tandem Diabetes Care, CeQur Simplicity, EOFLOW, Debiotech SA, F-Hoffmann-La Roche, Medzer.com, MicroPort Scientific, Novo Nordisk A/S, SOOIL Developments Co., Ltd., Terumo, ViCentra B.V., Ypsomed, Mannkind.

---

Key Questions Answered

---

What is the current size of the global insulin pump market?

The global insulin pump market achieved a valuation of USD 3.68 billion in 2022 and is projected to reach USD 6 billion by 2028.

What is the growth rate of the insulin pump market?

The insulin pump market is experiencing a compound annual growth rate (CAGR) of 8.46% from 2022 to 2028.

Who are the major players in the global insulin pump market?

The key players in the global insulin pump market include Insulet Corporation, Medtronic, and Tandem Diabetes Care.

What are the emerging trends in the insulin pump market?

The insulin pump market is witnessing emerging trends such as the introduction of new products and technological advancements in diabetes care, increasing demand for closed-loop technology, and a shift of patients from multiple daily injections to insulin pumps.

Which region dominates the global insulin pump market in terms of market share?

North America holds the largest market share in the global insulin pump market, accounting for 38.81%. This dominance can be attributed to factors such as a significant diabetic patient population in the region, continuous growth in diabetes healthcare expenditure, high awareness about insulin pumps, and the presence of a wide range of vendors in North America.